Is Leqvio Approved for High Cholesterol?
Yes, Leqvio (inclisiran) is FDA-approved to lower low-density lipoprotein cholesterol (LDL-C), the main driver of high cholesterol, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH).[1] It targets elevated LDL-C levels that persist despite maximum-tolerated statin therapy, often combined with ezetimibe or other lipid-lowering treatments.
How Does Leqvio Work?
Leqvio is a small interfering RNA (siRNA) that inhibits PCSK9 production in the liver, increasing LDL receptor availability to clear LDL-C from blood. A single 284 mg subcutaneous injection cuts LDL-C by up to 52% at day 17 and 56% at day 180, with effects lasting six months.[1][2] Patients receive two doses six months apart, then every six months.
Who Qualifies for Leqvio Treatment?
It's indicated for adults whose LDL-C remains high despite diet, exercise, and maximally tolerated statins. Clinical trials (ORION-9, -10, -11) showed 40-52% greater LDL-C reduction versus placebo, reducing major cardiovascular events by 34% over four years in high-risk patients.[2] Not for those with acute coronary syndrome, pregnancy, or hypersensitivity to inclisiran.
How Does Leqvio Compare to Other Cholesterol Drugs?
| Drug | Mechanism | Dosing | LDL-C Reduction | Common Side Effects |
|------|-----------|--------|-----------------|---------------------|
| Leqvio (inclisiran) | PCSK9 siRNA | SubQ every 6 months | 40-60% | Injection site reactions (8%), arthralgia (5%) |
| Repatha (evolocumab) | PCSK9 monoclonal antibody | SubQ every 2-4 weeks | 50-70% | Injection site reactions (5%), nasopharyngitis |
| Praluent (alirocumab) | PCSK9 monoclonal antibody | SubQ every 2-4 weeks | 45-65% | Injection site reactions (7%), flu-like symptoms |
| Nexletol (bempedoic acid) | ACL inhibitor (oral) | Daily pill | 15-25% | Increased uric acid, tendon rupture risk |
Leqvio stands out for infrequent dosing, improving adherence over weekly injections like Repatha.[2][3]
What Side Effects Should Patients Watch For?
Most common are mild injection-site reactions (redness, pain in 8%). Rare serious risks include allergic reactions or elevated liver enzymes. No increased muscle pain versus statins alone in trials.[1] Monitor for hypersensitivity; long-term data shows consistent safety up to four years.
Cost and Access Details
Leqvio costs about $3,250-$6,500 per dose (every 6 months), or $12,000+ annually without insurance. Patient assistance programs from Novartis cover copays for eligible U.S. patients.[4] Medicare Part D covers it, but prior authorization is required due to step therapy preferences for statins.
When Does Leqvio's Patent Expire?
Key U.S. patents on inclisiran expire in 2030 (composition of matter) with pediatric exclusivity to 2034; method-of-use patents extend protection possibly to 2034-2036.[5] No generics approved yet; biosimilar challenges unlikely before 2030.
[1]: FDA Label for Leqvio
[2]: NEJM: ORION-4 Trial Summary
[3]: Repatha Prescribing Information
[4]: Novartis Patient Assistance
[5]: DrugPatentWatch: Leqvio Patents